BioSig Technologies, Inc. (BSGM)
| Market Cap | 136.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -58.56M |
| Shares Out | 29.75M |
| EPS (ttm) | -2.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $4.70 |
| Previous Close | $4.59 |
| Change ($) | 0.11 |
| Change (%) | 2.40% |
| Day's Open | 4.56 |
| Day's Range | 4.40 - 4.81 |
| Day's Volume | 189,669 |
| 52-Week Range | 2.56 - 11.84 |
PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute PURE EP(tm) System to be highlighted in a Spotlight session by G...
Westport, CT, Jan. 14, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processi...
Industry-leading smart glasses technology expected to enhance the utility of BioSig's PURE EP™ System signal processing platform. Remote servicing intended to enable continued installations, u...
PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovatio...
Westport, CT, Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal pr...
NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease NeuroClear is set to commence experiments aimed at developing therapies for autonom...
BioSig Technologies, Inc. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. According to recent information published on WHO's 2019 Gl...
BioSig Technologies Inc (NASDAQ: BSGM), a medical device company, announced Friday a commercial milestone with respect to its FDA-approved PURE EP Systems. What Happened: Westport, Connecticut...
Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence
Westport, CT, Dec. 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal pr...
Company's flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020 Company's flagship product to be featured in live pa...
BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Business Development Update Conference Call (Transcript)
Westport, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical sign...
First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center
Westport, CT, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical sign...
BioSig Technologies Inc. (NASDAQ: BSGM) was absolutely crushed on Monday after the company announced that it would halt its midstage coronavirus study.
Shares of Biosig Technologies Inc. plunged 39.0% in active morning trading Monday, enough to pace all Nasdaq decliners, after the medical technology company halted a trial of its COVID-19 trea...
Westport, CT, Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralC...
Westport, CT, Sept. 30, 2020 (GLOBE NEWSWIRE) -- ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced the companies are exploring...
Westport, CT, Sept. 22, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (V...
Westport, CT, Sept. 21, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today a...
Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. Abstract concludes PURE EP™ System is abl...
Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical ...
Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Westport, CT, September 14, 2020 — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company develo...
Westport, CT, Sept. 09, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today a...
Westport, CT, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal...
Westport, CT, Aug. 25, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical si...
BioSig is two investment opportunities rolled into one. An early-stage electrophysiology play, and a late-stage COVID-19 vaccine candidate.
Westport, CT, Aug. 06, 2020 (GLOBE NEWSWIRE) --
Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today a...
Patient cases are set to commence in August Patient cases are set to commence in August
Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. government Company moves forward with the qualification to bid for contacts, grants an...
Westport, CT, July 30, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical s...
Chairman and CEO Kenneth L. Londoner to provide an update on the commercial rollout of PURE EP(tm) System, clinical development of BioSig’s pharmaceutical subsidiary and conduct virtual one-on...
Westport, CT, July 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announc...
ViralClear Chief Medical Officer Dr. Jerry Zeldis to Speak on Panel Titled “Arresting the Viral Replication Cycle” at B Riley FBR’s Infectious Disease Summit ViralClear Chief Medical Officer D...
Westport, CT, July 16, 2020 (GLOBE NEWSWIRE) -- Amended
A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
Adult patients hospitalized with COVID-19 are enrolled in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ Adult patients hospitalized with COVID-19 are enrolled in Austin, TX, ...
Registration would provide Company access to business with the federal government, including contract and grant opportunities Registration would provide Company access to business with the fed...
Westport, CT, July 08, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced tha...
Former President and CEO of the North American division of AstraZeneca Plc to join as Independent Director Former President and CEO of the North American division of AstraZeneca Plc to join as...
Westport, CT, June 29, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., toda...
Westport, CT, June 24, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with sever...
Westport, CT, June 22, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced t...
Initiation of randomized, double-blind, placebo-controlled Phase II trial of merimepodib, an orally administered broad-spectrum anti-viral, in combination with intravenous remdesivir in patien...
BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Phase II Human Trials for Broad-Spectrum Oral Anti-Viral for Treatment of COVID-19 (Transcript)
Randomized, double-blind, placebo-controlled Phase II trial of merimepodib to be conducted in adults with COVID-19 who are hospitalized and require supplemental oxygen or are on non-invasive v...
Company’s flagship biomedical signal processing platform highlighted in two scientific sessions presented by key opinion leaders from Mayo Clinic Company’s flagship biomedical signal processin...
About BSGM
BioSig Technologies, a medical device company, engages in developing and commercializing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company's proprietary product include precise uninterrupted real-time evaluation of electrograms electrophysiology system, a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electr... [Read more...]
| Industry Medical Devices | Founded 2009 |
| CEO Kenneth L. Londoner M.B.A., MBA | Employees 33 |
| Stock Exchange NASDAQ | Ticker Symbol BSGM |
Analyst Forecasts
According to one analyst, the rating for BSGM stock is "Buy" and the 12-month stock price forecast is 13.00.